Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug;15(8):803-817.
doi: 10.1002/alr.23566. Epub 2025 Mar 17.

The Effect of Systemic Bevacizumab on Epistaxis-Related Outcomes in Hereditary Hemorrhagic Telangiectasia: A Systematic Review and Meta-Analysis

William Li  1 , Jinzi Bai  1 , Anna Symons  1 , Jonathan Banting  1 , Joanne Rimmer  1   2   3
Affiliations
Meta-Analysis

The Effect of Systemic Bevacizumab on Epistaxis-Related Outcomes in Hereditary Hemorrhagic Telangiectasia: A Systematic Review and Meta-Analysis

William Li et al. Int Forum Allergy Rhinol. 2025 Aug.

Abstract

Background: The evidence-based recommendation for the use of systemic bevacizumab to treat refractory epistaxis in hereditary hemorrhagic telangiectasia (HHT) is based on limited and historical data. An updated synthesis of the available literature is warranted.

Methods: A systematic review and meta-analysis were conducted using PRISMA guidelines to evaluate the use of systemic bevacizumab for HHT-related epistaxis. A search was conducted using three databases up to September 2024 for studies assessing the effect of systemic bevacizumab use on epistaxis outcomes in HHT. Outcome measures included epistaxis severity score (ESS), hemoglobin, red blood cell (RBC), and iron transfusion requirements and adverse effects. Random effects meta-analysis was performed for change in ESS (ΔESS) and change in hemoglobin (ΔHb). Literature quality was assessed using the Joanne Briggs Institute critical appraisal tools.

Results: A total of 10 studies with 225 total patients were included. Systemic bevacizumab was associated with a significant posttreatment reduction in mean ESS of -3.33 (95% CI -3.62 to -3.03) and a significant increase in mean Hb of 2.38 g/dL (95% CI 1.45-3.30) compared to pretreatment. All cohort studies found a significant reduction in RBC and iron transfusions following systemic bevacizumab treatment. The most frequently reported adverse effect of systemic bevacizumab was hypertension.

Conclusion: Systemic bevacizumab is associated with significant improvements in epistaxis severity, hemoglobin, and transfusion requirements in HHT-related epistaxis. Adequately powered studies are required to strengthen this finding. Patient selection criteria, standardized maintenance dosing, and long-term treatment data require further study.

Keywords: bevacizumab; epistaxis; hereditary hemorrhagic telangiectasia.

PubMed Disclaimer

References

    1. F. S. Govani and C. L. Shovlin, “Hereditary Haemorrhagic Telangiectasia: A Clinical and Scientific Review,” European Journal of Human Genetics 17, no. 7 (2009): 860–871.
    1. A. Kritharis, H. Al‐Samkari, and D. J. Kuter, “Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management From the Hematologist's Perspective,” Haematologica 103, no. 9 (2018): 1433–1443.
    1. C. J. Gallione, G. M. Repetto, E. Legius, et al., “A Combined Syndrome of Juvenile Polyposis and Hereditary Haemorrhagic Telangiectasia Associated With Mutations in MADH4 (SMAD4),” Lancet 363, no. 9412 (2004): 852–859.
    1. G. Lenato and G. Guanti, “Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects,” Current Pharmaceutical Design 12, no. 10 (2006): 1173–1193.
    1. J. McDonald and D. A. Stevenson, Hereditary Hemorrhagic Telangiectasia (University of Washington, 2000), https://www.ncbi.nlm.nih.gov/books/NBK1351/.

MeSH terms

LinkOut - more resources